Trials / Withdrawn
WithdrawnNCT03688568
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Phase 2 Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Indiana University · Academic / Other
- Sex
- All
- Age
- 6 Months – 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy. Funding Source - FDA OOPD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib Mesylate | Imatinib given orally as dose escalation treatment. |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2020-09-01
- Completion
- 2021-09-01
- First posted
- 2018-09-28
- Last updated
- 2021-02-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03688568. Inclusion in this directory is not an endorsement.